Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential July 30, 2026 VRB-103, a potential once-weekly, selective oral amylin analog, is being evaluated in a Phase 1 study as both a monotherapy and in combination with VRB-101 (oral ecnoglutide), a once-weekly oral GLP-1 analog Once-weekly oral dosing of both VRB-103 and VRB-101 enabled by clinically validated, potential best-in-class peptide delivery platform VRB-103 is the first known, once-weekly oral amylin analog currently in clinical development Initial data currently anticipated by the end of 2026
Titan Group: First Half 2026 Results July 30, 2026 Strong sales performance with continued margin expansion, while accelerating the integration of new acquisitions
Western Europe’s Fashion E-commerce Market Matures, Representing 20% of Online Consumer Spending as Gen Z Drives momentum July 30, 2026 Second-hand platforms and value-focused retailers are disrupting Western Europe’s fashion market, which accounts for nearly one-fifth of online spending
Arch Construction Risk Report Reveals Top Challenges Facing Sector Amid Rising Volatility July 30, 2026 Growing complexity and interconnected risks driving up insurance spend in construction.
Fluidra Delivers a Strong First Half of 2026 and Maintains Positive Momentum in a Dynamic Environment July 30, 2026 Sales increased by 5% at constant FX to €1,258 million, driven by Fluidra’s customer focus and consistent execution Adjusted EBITDA grew by 6% at constant FX to €321 million, supported by firm cost discipline The company signed an agreement to acquire Hydrapro, a French manufacturer specializing in water treatment, to further support its growth Fluidra launches a €40 million share buy-back program and maintains full-year guidance
Iksuda receives US FDA IND clearance for IKS04 July 30, 2026 CA242-directed ADC approved for assessment in Phase 1 trials in patients with GI cancers The ‘IKS04 Regimen’ is an innovative dosing approach for an ADC which is employed to overcome the challenge of solid tumour penetration for high-potency payloads
SES Reports H1 2026 Results & Reiterates Full-Year Outlook July 30, 2026 SES S.A. announces financial results for the three and six months ended June 30, 2026. H1 2026 Performance (€ million) H1 2026 as reported (1) H1 2025 as reported (1) ∆ At constant FX (2) H1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.17 1.08 1.08 Revenue 1,602 978 [...]
AB InBev Reports Second Quarter 2026 Results July 30, 2026 Solid top- and bottom-line performance: Revenue up by 5.6%, Beer volume growth of 1.1% and a 23.4% Underlying EPS increase
KBRA Assigns Preliminary Ratings to Barings Euro Middle Market 2024-1 (Reset) July 29, 2026 KBRA UK (KBRA) assigns preliminary ratings to seven classes of notes issued by Barings Euro Middle Market 2024-1 (Reset), a cash flow collateralized loan obligation (CLO) backed by a diversified portfolio of middle market corporate loans. The original transaction closed on 16 December 2024 as a static CLO. This transaction refinances the original CLO by [...]
Everest Reports Second Quarter 2026 Results July 29, 2026 Annualized 14.2% Net Income ROE and 14.9% Net Operating Income ROE Annualized Total Shareholder Return of 16.8% $559 million of Net Income and Combined Ratio of 92.0% $317 million of Underwriting Income and Combined Ratio of 90.0% from our Core Businesses* Repurchased $395 million of Common Shares During the Quarter